As the pharmaceutical landscape evolves at an unprecedented pace, the need for a collaborative, science-first forum has never been greater. This October 25–28, the global scientific community will converge at the Ernest N. Morial Convention Center in New Orleans for AAPS PharmSci 360, an event that serves as the nexus for innovation, regulatory strategy, and professional development in the drug discovery and development lifecycle.
The 2026 edition promises to be more than just a conference; it is a critical autopsy of current industry challenges and a roadmap for future breakthroughs. With thousands of attendees ranging from early-stage researchers to C-suite executives, PharmSci 360 provides a rare vantage point into the methodologies—from AI-driven drug discovery to sophisticated organ-on-a-chip models—that are currently defining the next generation of patient care.
The Strategic Imperative: Bridging Research and Reality
The fundamental mission of AAPS PharmSci 360 is to bridge the gap between bench-side innovation and the realities of commercialization and regulation. Representing a "who’s who" of the biopharmaceutical ecosystem—including titans like AstraZeneca, Merck, and the Mayo Clinic, as well as specialized firms like Rx-360—the event emphasizes the entire product lifecycle.
For early-career scientists, the event offers a unique opportunity to witness the integration of emerging technologies into existing regulatory frameworks. The inclusion of "Innovator-Curated" tracks this year represents a significant evolution in conference programming, placing the narrative power directly into the hands of field experts to address the most pressing bottlenecks in modern drug development.
A Chronological Roadmap of Key Scientific Sessions
The four-day program is meticulously structured to address the most critical hurdles in the pharmaceutical pipeline.

Monday, October 26: Navigating Regulatory and Biological Complexity
The first full day of programming dives into the mechanics of development speed and the biology of disease resistance. A standout session, "What Actually Drives Development Speed? An Executive-Level Autopsy of Drug Development Delays," will feature insights from leaders at Rx-360 and Blue Oaks Biotech, promising to offer a candid look at the inefficiencies that hinder speed-to-market.
Technical sessions on Monday shift toward advanced biological modeling. Dr. Nagendra Chemuturi of Eli Lilly will provide a deep dive into ICH S12 compliance for biodistribution and persistence, a crucial topic for those working in gene therapy and novel biotherapeutics. Additionally, the intersection of advanced cellular models will be explored by Dr. Kim L.R. Brouwer, while Dr. Mandip Singh Sachdeva will tackle the complex topic of PD-L1 exosomes and their role in reprogramming cancer resistance—a topic with profound implications for oncology drug development.
Tuesday, October 27: The Rise of NAMs and Precision Medicine
Tuesday focuses on the transition toward New Approach Methodologies (NAMs) and personalized medicine. With the FDA and global regulators increasingly looking toward non-animal testing models, the sessions on Quantitative Systems Toxicology and Microphysiological Systems—led by experts from Simulations Plus and Xellar Biosystems—are set to be highlights.
Clinical relevance remains at the heart of these discussions, as evidenced by Dr. Jessica Atieh’s examination of the clinical consequences of GLP-1-induced gastric emptying. As GLP-1 agonists continue to dominate headlines, understanding their secondary physiological impacts is essential for clinicians and developers alike. Furthermore, the focus on "Nanomedicine in Translation" by AstraZeneca’s Dr. Annette Bak serves as a reminder of how refined drug delivery systems continue to define therapeutic outcomes.
Wednesday, October 28: Modeling, Regulation, and the Future
The final day turns toward the long-term future of the industry, focusing on pediatric data standards, multispecific biologics, and the nuances of PBPK modeling. The "Hot Topic" session regarding global regulatory alignment on pediatric drug data will feature high-level participants from the U.S. FDA, Health Canada, and the European Paediatric Formulation Initiative. This panel underscores the global nature of modern drug development and the vital importance of harmonized international standards.

Supporting Data and Technical Innovation
The 2026 agenda is bolstered by a significant expansion in the exhibit hall. The introduction of dedicated USP (United States Pharmacopeia) sessions marks a major value-add for attendees. By providing direct access to USP scientists, the conference offers clarity on complex topics like inhalation standards, excipient quality, and the regulatory pathway for novel delivery systems.
Furthermore, the integration of cutting-edge vendors—including 10x Genomics, Agilent, and Thermo Fisher Scientific—ensures that attendees can match their theoretical learning with practical, deployable technological solutions. These interactions are designed to catalyze the transition from conceptual research to high-throughput implementation.
Official Perspectives: Integrity and Public Health
The conference is anchored by high-profile plenary sessions that ground the technical discussions in a broader societal context.
- Public Health Leadership: Dr. Julie Gerberding, President and CEO of the Foundation for the National Institutes of Health (FNIH), will open the conference, offering a high-level view of how public-private partnerships are currently addressing global health crises.
- Technological Transformation: Dr. David Berry of Averin Capital will conclude the event, providing an investment and market-based perspective on how artificial intelligence and biotechnology are fundamentally altering the economics of the pharmaceutical sector.
Moreover, the emphasis on Research Integrity, led by Brian Nosek, signals the industry’s commitment to self-regulation and scientific rigor. By dedicating a specific track to the reproducibility and ethics of research, AAPS is fostering a culture of accountability that is essential for maintaining public trust in an era of rapid scientific advancement.
Implications for the Industry
The implications of the discussions at PharmSci 360 extend far beyond the New Orleans convention floor. Several key themes are poised to shape the industry for the next decade:

- The Dominance of NAMs: The shift away from traditional animal models toward organ-on-a-chip and quantitative systems toxicology is not just a trend; it is a regulatory shift. Companies that master these methodologies early will likely face fewer hurdles during the IND (Investigational New Drug) application process.
- Career Evolution in the Age of AI: The "Careers 360" programming—which includes AI skill-building and startup funding advice—acknowledges that the skill set required for a modern pharmaceutical scientist is vastly different from that of a decade ago. The integration of data science into traditional wet-lab biology is now a prerequisite for professional success.
- Global Harmonization: The focus on regulatory sessions involving Health Canada and the FDA indicates a continued push toward global drug development standards. For small and mid-sized firms, these sessions are critical for understanding how to design clinical trials that satisfy multiple international regulatory bodies simultaneously.
Conclusion: Why Participation Matters
AAPS PharmSci 360 is a crucible for professional and scientific development. Whether you are a doctoral candidate looking to bridge the gap between academic research and industry application, or a seasoned executive managing a portfolio of complex biologics, the breadth of the 2026 program is designed to provide actionable insights.
As the industry faces the dual pressures of accelerated development timelines and more rigorous regulatory scrutiny, the community-building aspect of this event is its greatest asset. By bringing together the disparate voices of the pharmaceutical world—from the regulator to the researcher to the venture capitalist—PharmSci 360 ensures that the path forward is paved with both innovation and integrity.
With registration now open, industry professionals are encouraged to secure their place in what promises to be the most comprehensive scientific gathering of the year. Join your colleagues in New Orleans this October to contribute to the ongoing dialogue that will ultimately define the future of medicine.
For more information on the full schedule and to register for AAPS PharmSci 360, please visit the official AAPS website. Sponsored content provided by the American Association of Pharmaceutical Scientists (AAPS).
